Hepatocyte-protective and anti-oxidant effects of rifampicin on human chronic hepatitis C and murine acute hepatocyte disorder

Kataoka,Kazuhiro; Kono,Yutaka; Sugimoto,Masanobu; Furuichi,Yasuhiro; Shichiri,Masayoshi; Tanaka,Yujiro

doi:10.3892/etm.2010.159

November-December 2010 Volume 1 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-December 2010 Volume 1 Issue 6

Full Size Image

Article

Hepatocyte-protective and anti-oxidant effects of rifampicin on human chronic hepatitis C and murine acute hepatocyte disorder

Authors:
- Kazuhiro Kataoka
- Yutaka Kono
- Masanobu Sugimoto
- Yasuhiro Furuichi
- Masayoshi Shichiri
- Yujiro Tanaka
View Affiliations / Copyright

Affiliations: GeneCare Research Institute Co., Ltd., Kamakura 247-0063, Japan, Kitasato University School of Medicine, Minami-ku, Sagamihara 252-0374, Japan, Department of General Medicine, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8519, Japan
Pages: 1041-1047
|
Published online on: September 29, 2010

https://doi.org/10.3892/etm.2010.159
Expand metrics +

Abstract

Rifampicin (RFP) is a semisynthetic antibiotic derived from the rifamycins and is one of the most commonly used pharmaceutical compounds worldwide in the treatment of tuberculosis. We previously reported that low-dose and long-term oral administration of RFP to 6 hepatitis C virus-related liver cirrhosis patients who were at high risk for presenting with hepatocellular carcinoma (HCC) resulted in a marked suppression of the occurrence of HCC without showing an adverse effect. The underlying mechanism was found to be due to the anticancer effect based on the potent anti-angiogenic properties of RFP. The present study revealed that RFP has an additional hepatocyte-protective effect by lowering the release of hepatic enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in chronic hepatitis C patients. Experimentally, we were able to show that RFP had hepatocyte-protective effects in acute hepatocyte disorder models of mice and rats induced by concanavalin A and by D-galactosamine, respectively: RFP significantly prevented an increase in the levels of ALT, AST and lactate dehydrogenase in these animal models. In addition, we found that RFP had a strong anti-oxidant action which was approximately three times stronger than the action of silibinin, an anti-inflammatory agent of human hepatic stellate cells, implicating that the hepatocyte-protective effects of RFP are mediated by its anti-oxidant activity. These results reveal that oral administration of RFP exerts not only a prophylactic effect on the occurrence or recurrence of HCC for an extensive period of time, but also exerts hepatocyte-protective effects on both human chronic hepatitis C and acute hepatocyte disorder in rodent models, and the anti-oxidant activity of RFP is implicated to participate in the latter effects.

View Figures

View References

1.	Shichiri M, Fukai N, Kono Y and Tanaka Y: Rifampicin as an oral angiogenesis inhibitor targeting hepatic cancers. Cancer Res. 69:4760–4768. 2009. View Article : Google Scholar : PubMed/NCBI
2.	Pal S, Polyak SJ, Bano N, et al: Hepatitis C virus induces oxidative stress, DNA damage and modulates the DNA repair enzyme NEIL1. J Gastroenterol Hepatol. 25:627–634. 2010. View Article : Google Scholar : PubMed/NCBI
3.	Nomura T, Kikuchi M, Kubodera A and Kawakami Y: Proton-donative antioxidant activity of fucoxanthin with 1,1-diphenyl-2-picrylhydrazyl (DPPH). Biochem Mol Biol Int. 42:361–370. 1997.PubMed/NCBI
4.	Tiegs G and Gantner F: Immunotoxicology of T cell-dependent experimental liver injury. Exp Toxicol Pathol. 48:471–476. 1996. View Article : Google Scholar : PubMed/NCBI
5.	Czaja MJ, Flanders KC, Biempica L, Klein C, Zern MA and Weiner FR: Expression of tumor necrosis factor-alpha and transforming growth factor-beta 1 in acute liver injury. Growth Factors. 1:219–226. 1989. View Article : Google Scholar : PubMed/NCBI
6.	Trappoliere M, Caligiuri A, Schmid M, et al: Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol. 50:1102–1111. 2009. View Article : Google Scholar : PubMed/NCBI
7.	Huang R, Okuno H, Takasu M, Shiozaki Y and Inoue K: Protective effect of rifampicin against acute liver injury induced by carbon tetrachloride in mice. Jpn J Pharmacol. 69:325–334. 1995. View Article : Google Scholar : PubMed/NCBI
8.	Acocella G: Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet. 3:108–127. 1978. View Article : Google Scholar
9.	Whiteman M and Halliwell B: Prevention of peroxynitrite-dependent tyrosine nitration and inactivation of alpha1-antiproteinase by antibiotics. Free Radic Res. 26:49–56. 1997. View Article : Google Scholar : PubMed/NCBI
10.	Kalpana T, Karunakar N, Reddy MS, Prabhakar MC and Krishna DR: Assessment of antioxidant activity of some antileprotic drugs. Arzneimittelforschung. 51:633–637. 2001.PubMed/NCBI
11.	Loguercio C and Federico A: Oxidative stress in viral and alcoholic hepatitis. Free Radic Biol Med. 34:1–10. 2003. View Article : Google Scholar : PubMed/NCBI
12.	Morisco F, Verde V, Fogliano V, et al: Oxidative status in chronic hepatitis C: the influence of antiviral therapy and prognostic value of serum hydroperoxide assay. Free Radic Res. 38:573–580. 2004. View Article : Google Scholar : PubMed/NCBI
13.	Berkson BM: A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. Med Klin. 94(Suppl 3): 84–89. 1999. View Article : Google Scholar : PubMed/NCBI
14.	Iseri E, Ercan MT, Kas HS and Hincal AA: The in vivo distribution of the 99mTc-labelled albumin and gelatin microspheres of a tuberculostatic agent, rifampicin. Boll Chim Farm. 130:66–70. 1991.PubMed/NCBI
15.	Takeda K, Watanabe J, Inoue K and Kanamura S: Rifampicin suppresses hepatic CYP2E1 expression and minimizes DNA injury caused by carbon tetrachloride in perivenular hepatocytes of mice. Alcohol Clin Exp Res. 24(Suppl 4): 87–92. 2000.PubMed/NCBI
16.	Tiegs G: Experimental hepatitis and role of cytokines. Acta Gastroenterol Belg. 60:176–179. 1997.PubMed/NCBI
17.	Nicoletti F, Di Marco R, Zaccone P, et al: Murine concanavalin A-induced hepatitis is prevented by interleukin 12 (IL-12) antibody and exacerbated by exogenous IL-12 through an interferon-gamma-dependent mechanism. Hepatology. 32:728–733. 2000. View Article : Google Scholar : PubMed/NCBI
18.	Ishiwata Y, Yokochi S, Hashimoto H, Ninomiya F and Suzuki T: Protection against concanavalin A-induced murine liver injury by the organic germanium compound, propagermanium. Scand J Immunol. 48:605–614. 1998. View Article : Google Scholar : PubMed/NCBI
19.	Doria G and Agarossi G: Inhibition of the immune response in vitro by rifampicin and derivatives. Scand J Respir Dis. (Suppl 84): 23–26. 1973.PubMed/NCBI
20.	Ziglam HM, Daniels I and Finch RG: Immunomodulating activity of rifampicin. J Chemother. 16:357–361. 2004. View Article : Google Scholar
21.	Shichiri M and Tanaka Y: Inhibition of cancer progression by rifampicin: involvement of antiangiogenic and anti-tumor effects. Cell Cycle. 9:64–68. 2010. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Hepatocyte-protective and anti-oxidant effects of rifampicin on human chronic hepatitis C and murine acute hepatocyte disorder

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles